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Abstract
Background: Mesenchymal stromal cells (MSCs) and renal stem/progenitors improve the recovery of acute kidney injury
(AKI) mainly through the release of paracrine mediators including the extracellular vesicles (EVs). Several studies have
reported the existence of a resident population of MSCs within the glomeruli (Gl-MSCs). However, their contribution
towards kidney repair still remains to be elucidated. The aim of the present study was to evaluate whether Gl-MSCs and
Gl-MSC-EVs promote the recovery of AKI induced by ischemia-reperfusion injury (IRI) in SCID mice. Moreover, the effects
of Gl-MSCs and Gl-MSC-EVs were compared with those of CD133+ progenitor cells isolated from human tubules of the
renal cortical tissue (T-CD133+ cells) and their EVs (T-CD133+-EVs).
Methods: IRI was performed in mice by clamping the left renal pedicle for 35 minutes together with a right
nephrectomy. Immediately after reperfusion, the animals were divided in different groups to be treated with:
Gl-MSCs, T-CD133+ cells, Gl-MSC-EVs, T-CD133+-EVs or vehicle. To assess the role of vesicular RNA, EVs were
either isolated by floating to avoid contamination of non-vesicles-associated RNA or treated with a high dose
of RNase. Mice were sacrificed 48 hours after surgery.
Results: Gl-MSCs, and Gl-MSC-EVs both ameliorate kidney function and reduce the ischemic damage post IRI by
activating tubular epithelial cell proliferation. Furthermore, T-CD133+ cells, but not their EVs, also significantly contributed
to the renal recovery after IRI compared to the controls. Floating EVs were effective while RNase-inactivated EVs were
ineffective. Analysis of the EV miRnome revealed that Gl-MSC-EVs selectively expressed a group of miRNAs, compared to
EVs derived from fibroblasts, which were biologically ineffective in IRI.
Conclusions: In this study, we demonstrate that Gl-MSCs may contribute in the recovery of mice with AKI induced by IRI
primarily through the release of EVs.
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Background
Acute kidney injury (AKI) is a major clinical disorder
that affects more than 20% of hospitalized patients. Fur-
thermore, the adjusted odds ratio for hospital mortality
in patients that develop AKI stands at 4:1 [1, 2]. Out of
all the causes of AKI, ischemia-reperfusion injury (IRI)
signifies to be one of the most important, as it is charac-
terized by severe tubular damage associated with rapid
worsening of the renal function [3]. Moreover, IRI may
subsequently develop into chronic kidney disease (CKD),
mainly due to fibroblast proliferation and the deposition
of extracellular matrix.
Regeneration of injured tubular and endothelial cells
after AKI may occur through multiple mechanisms
including the de-differentiation of surviving resident
cells [4–8] and/or the intrinsic ability of resident pro-
genitor cells to proliferate and differentiate into new
renal cells [9–14]. A population of resident renal pro-
genitor cells expressing the human stem cell antigen
CD133 and the embryonic renal marker PAX2 has been
identified in the tubular compartment [9]. Furthermore,
Sagrinati et al. reported the presence of renal progenitor
cells characterized by the co-expression of CD133 and
CD24 within the Bowman’s capsule [11]. Subsequently,
CD133+ progenitor cells were also found to be present
in different compartments of the nephron [9, 11–13, 15].
Several authors demonstrated that these progenitor cells
could contribute towards kidney repair after injury in
different murine models of AKI [9, 10, 12, 16]. In
addition, over the last decade, numerous studies per-
formed in animal models of AKI and CKD have reported
the beneficial effects of mesenchymal stromal cells
(MSCs) not only in the recovery of renal function after
IRI, but also in reducing the progression of the chronic
damage that followed [17–23]. The mechanism by which
MSCs exert these effects seems to be primarily due to a
paracrine action on the target cells rather than transdif-
ferentiation into resident cells [24–27]. It is well known
that MSCs release soluble factors which promote the
recovery of damaged renal cells [28–31]. Among these
factors, extracellular vesicles (EVs) have been implicated
to play a role in the paracrine actions of MSCs [32]. EVs
are circular cellular membrane fragments that are re-
leased from a given cell type and influence target cells
by delivering proteins, lipids and nucleic acids [33–37].
Amidst various types of nucleic acids transported by
EVs, the capacity of mRNAs to induce epigenetic
changes in target cells in murine models of AKI using
MSC-derived EVs has been well demonstrated by several
authors [38–40]. In addition, several studies have also
demonstrated the presence of microRNAs (miRNA) in
EVs that could be transferred to the target cells modulat-
ing their phenotype [36, 41]. Other than nucleic acids,
proteins carried by EVs also have significant effects on
target cells. For instance, Sallustio et al. recently reported
that the protein decorin carried by EVs from adult renal
stem/progenitor cells improved the survival of tubular epi-
thelial cells in an in vitro toxic AKI model [42].
MSCs are stem cells that have been reported to reside
in almost all organs. Furthermore, they have also been
identified to be present within the glomeruli of both
mice and human [43, 44]. However, their role in the
repair of kidney injury is still unknown.
The aim of the present study was to evaluate whether
the MSCs derived from human glomeruli (Gl-MSCs)
and their EVs (Gl-MSC-EVs) promote the recovery of
AKI induced by IRI in SCID mice. Furthermore, the ef-
fects of Gl-MSCs and Gl-MSC-EVs were compared with
those of CD133+ progenitor cells isolated from human
tubules of the renal cortical tissue (T-CD133+ cells) and
their EVs (T-CD133+-EVs).
Methods
Isolation and characterization of different resident renal
stem/progenitor cell populations
Normal portions of renal cortex were obtained from sur-
gically removed kidneys of cancer patients with informed
consent, obtained in accordance with the Declaration of
Helsinki and after approval by the ethic committee of
the Azienda Ospedaliera Universitaria, Città della Salute
e della Scienza, Torino (N. 168/2014). After dissection
and passage through a graded series of mesh (60 and
120 mesh per inch), T-CD133+ cells were isolated form
the tubular fraction by magnetic cell sorting, using the
MACS system (Miltenyi Biotec, Auburn, AL, USA). T-
CD133+ cells were cultured and expanded as previously
described [9]. The glomeruli were recovered from the
top of the 120-mesh sieve and collected at the bottom of
a conical tube by low-speed centrifugation (300 g, 5 mi-
nutes). To obtain Gl-MSCs, the visceral layer of the
Bowman’s capsule was removed mechanically by several
rounds of aspirations/expulsions using a 10-ml pipette,
followed by an enzyme digestion for 2 minutes with col-
lagenase I (Sigma-Aldrich, St. Louis, MO. USA). The
decapsulated glomeruli were then collected by low-speed
centrifugation and transferred to a fibronectin-coated
T25 flask and cultured as previously described [44].
Cytofluorimetric analyses were performed as previ-
ously described [9, 44] using the following antibodies:
anti-CD105, -CD29, -CD73, -CD44, -CD133, -CD146,
-CD24, -CD31, -CD90, -CD45 (all from Mitenyi Biotech,
Auburn, AL, USA). T-CD133+ cells co-expressed CD73,
CD44, CD29, CD90, CD146 and CD24; no expression
of CD45, CD31 and CD105 was detected (Table 1).
Gl-MSCs were positive for surface markers character-
istic of MSCs, such as CD29, CD73, CD105, CD146,
CD44, CD90 and for CD24. Gl-MSCs were negative
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for CD133 and for specific hematopoietic (CD45) and
endothelial markers (CD31) (Table 1). Human dermal
fibroblasts were used as control (Lonza, Basel,
Switzerland). FACS analyses indicated that the fibro-
blasts expressed CD73, CD44, CD29 and CD24
(Table 1).
Isolation and characterization of EVs derived from Gl-MSCs
and T-CD133+ cells
Briefly, healthy stem/progenitor cells were incubated in
serum-free RPMI 1640 overnight at 37 °C. Post incuba-
tion, the cell supernatant was collected and centrifuged
at 3,000 g for 20 minutes to remove cell debris and
apoptotic bodies. This was followed by ultracentrifuga-
tion at 100,000 g for 2 hours at 4 °C (Beckman Coulter
Optima L-90 K, Fullerton, CA, USA) to pellet the EVs
[38, 45]. The EVs obtained were then resuspended in
RPMI containing 1% dimethyl sulfoxide (DMSO, Sigma-
Aldrich) and stored at -80 °C until further use.
In order to trace EVs by fluorescent microscopy post
in vivo injection, they were labelled with PKH26 dye (a
red fluorescent aliphatic cromophore intercalating into
lipid bilayers) as per manufacturer’s instructions (PKH26
dye, Sigma-Aldrich). After labelling, the EVs were
washed with PBS by ultracentrifugation at 100,000 g for
2 hours at 4 °C.
To separate membrane-enclosed vesicles from aggregates
of protein and other molecules (e.g. extra-vesicle RNAs),
EVs were isolated by a floating process into a gradient, as
described previously [46, 47]. Briefly, EVs from 80 million
Gl-MSCs were resuspended in 1.35 ml of buffer (0.25 M
sucrose, 10 mM Tris pH 8 and 1 mM EDTA), transferred
to a SW55Ti rotor tube (Beckman Coulter) and mixed with
60% stock solution of Optiprep (Sigma-Aldrich) in a 1:1 ra-
tio. Next, 1.2 ml of 20% Optiprep solution was layered on
top, followed by 1.1 ml of 10% Optiprep solution. The tubes
were then ultracentrifuged at 350,000 g for 1 hour at 4 °C.
Five fractions of 1 ml were collected from the top of the
tubes, each fraction was diluted in 20 ml PBS and ultracen-
trifuged at 100,000 g for 1 hour at 4 °C to pellet the EVs.
Nanosight analyses (not shown) indicated that fraction 2
contained vesicles with a similar size range of exosomes,
and therefore that fraction was used for the in vivo experi-
ments. Treatment with 0.2 μg/mL RNase did not inactivate
RNA present in the floating fraction (0.9 ng/mL untreated;
1.0 ng/mL RNase floating EVs).
To characterize the phenotype of EVs, cytofluorimetric
analysis was performed as previously described [45].
Briefly, EVs were incubated for 15 minutes at 4 °C with
the following antibodies: anti-CD24, -CD29, -CD146,
-CD133 (Miltenyi Biotech), -CD107, (Becton Dickinson,
Franklin Lakes, NJ, USA) and SSEA4 (R&D Systems,
Minneapolis, MN, USA). Mouse nonimmune isotypic
IgG (Miltenyi Biotech) was used as control. For each
preparation of EVs, 5000 particles were acquired using
the Guava easyCyte™ Flow Cytometer (EMD Millipore,
Billerica, MA, USA) and analysed with the InCyte™
software.
EV size and concentration were measured by the
NanoSight LM10 instrument (NanoSight Ltd, Amesbury,
UK) equipped with a 405 nm laser and the nanoparticle
tracking analyses (NTA) software version 2.3. Three vid-
eos of 30 seconds duration were recorded in order to
perform the analyses.
RNase treatment, RNA isolation and analyses
For selected experiments, EVs were treated with 5 μg/ml
of RNase for 1 hour at 37 °C. The reaction was stopped
by adding 1 U of RNase inhibitor (Ambion, Austin, TX,
USA) per 5 ng of RNAse used, and the EVs washed and
pelleted by ultracentrifugation (2 hours at 100,000 g).
RNA was extracted from cells and EVs using the mir-
Vana RNA isolation kit (Applied Biosystems, Foster City,
CA, USA) as per the manufacturer’s protocol. The quan-
tification of RNA was performed using the Nanodrop
spectrophotometer (ND-1000; Nanodrop, Wilmington,
DE, USA), and the quality of RNA was assessed by capil-
lary electrophoresis on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) using the
Total Eukaryotic Pico RNA kit.
miRNA expression and target gene enrichment analysis
To investigate miRNAs carried by Gl-MSC-EVs and fibro-
blast EVs, 60 ng of input RNA was run on TaqMan™ Array
Human MicroRNA A card (Thermo Fisher Scientific,
Waltham, MA, USA), that profiles 365 human mature
miRNAs by qRT-PCR. Raw Ct values were analysed using
the SDS 2.3 software with automatic baseline and thresh-
old settings. The data were expressed as Relative Quantifi-
cation (RQ) using the ΔΔCt method and RNU6B was
used as housekeeping gene for normalization. To identify
miRNA specifically expressed and upregulated in Gl-
Table 1 Phenotype of different renal stem/progenitor cell populations
T-CD133+ Gl-MSCs Fibroblasts
Positive CD90 CD73 CD44 CD29 CD24 CD133 CD146 CD90 CD73 CD44 CD29 CD24 CD105 CD146 CD73 CD44 CD29 CD24
Negative CD45 CD31 CD105 CD45 CD31 CD133 CD45 CD133 CD90 CD31 CD146 CD105
T-CD133+ CD133+ progenitor cells isolated from human tubules of the renal cortical tissue, Gl-MSCs Resident population of MSCs within glomeruli
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MSC-EVs, we applied different Ct cutoff levels for fibro-
blast EVs (Ct >35, not expressed) and Gl-MSC-EVs (Ct
<35, expressed). Target prediction and biological process
enrichment analysis was conducted using Funrich V3 ana-
lysis tool [48]. Only the biological process of target genes
with a p value <0.05 were considered as significantly
enriched.
Animal model of monolateral kidney IRI
All procedures were approved by the Ethics Committee
of the University of Torino and conducted in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals. Male SCID mice
(Charles River Laboratories, Wilmington, MA, USA)
aged 7 to 8 weeks and weighing 22 to 26 g were anesthe-
tized with an intramuscular (i.m.) injection of zolazepam
80 mg/kg and xilazina 16 mg/kg. Postoperatively, the an-
imals were closely monitored, and ketorolac (5 mg/kg)
was administered as an analgesic if required. Under ster-
ile conditions, a small mid laparotomy was made, the left
kidney exposed and the renal pedicle was clamped for
35 minutes using a nontraumatic vascular clamp (Fine
Science Tools, Foster City, CA, USA). Immediately after
clamping the left renal pedicle, a right nephrectomy was
performed using a subcapsular technique. Briefly, after
isolation and ligation of the right kidney pedicle, the
renal capsule was dissected and the renal parenchyma
exposed. The nephrectomy was performed by the inci-
sion of the renal parenchyma leaving the capsule in situ.
This procedure allows an accurate hemostasis to exclude
bleeding due to the failure of the ligation of the renal
pedicle. The laparotomy incision was temporarily closed
during ischemia and the body temperature was main-
tained at 37 °C during the surgical intervention by pla-
cing the animals on a heating plate. Reperfusion of the
kidney was then confirmed visually after removing the
clamp. The abdominal incision was closed with a 6-0 silk
suture. After surgical intervention, the mortality rate
was approximately 10%.
In order to evaluate the effects of cells or EVs in
AKI-IRI mice, the animals were divided in ten groups
based on the different treatments (Table 2). The dose
of EVs used was selected as the number of EVs pro-
duced overnight by 1 × 105 cells under serum starva-
tion (T-CD133+ -EVs: 480 × 106/mouse; Gl-MSC-EVs:
400 × 106/mouse; Gl-MSC-EV-float: 400 × 106/mouse;
F-EVs: 230 × 106/mouse). For all the experiments, cells
cultured up to passage 6 were detached by trypsin
(Sigma-Aldrich), washed and resuspended in PBS
(Lonza). The cells were injected intravenously (120 μl
injecting volume, i.v.) through the tail vein. All the
animals were sacrificed at day 2 after surgery. For
bio-distribution analysis, mice were sacrificed at 1, 6
and 24 hours after surgery.
In order to evaluate the long-term effect of Gl-MSCs
and T-CD133+ cells on kidney function post IRI, and
also to check the potential development of malignancy,
supplementary experiments were performed in mice.
The animals were divided into four groups according to
the treatment administered intravenously immediately after
surgery: normal mice (n = 5); IRI-CTL mice (n = 6) injected
with vehicle alone; IRI-Gl-MSC mice (n = 6) injected with
Table 2 Schematic representation of the groups of mice used in the study
Treatment Doses No. animals Time of sacrifice
Normal - 5 48 h
- 5 3 weeks
Sham-operated - 5 48 h
IRI-CTL (vehicle) - 8 48 h
- 6 3 weeks
Cells IRI-Gl-MSC 105 cells 8 48 h
105 cells 6 3 weeks
IRI-T-CD133+ 105 cells 8 48 h
105 cells 6 3 weeks
EVs IRI-Gl-MSC-EVs 400 × 106 EVs* 8 48 h
IRI-Gl-MSC-EVs-float 400 × 106 EVs* 6 48 h
IRI-RNase-Gl-MSC-EVs 400 × 106 EVs* 8 48 h
IRI-T-CD133+-EVs 480 × 106 EVs* 8 48 h
IRI-F-EVs 230 × 106 EVs* 5 48 h
IRI ischemia-reperfusion injury, CTL control, Gl-MSC glomerular mesenchymal stromal cells, T-CD133+-EVs T-CD133+-derived EVs, EVs extracellular vesicles, Gl-MSC-EVs Gl-MSC-
derived EVs, Gl-MSC-EVs-float Gl-MSC-derived EVs isolated through floating test, RNase-Gl-MSC-EVs Gl-MSC-derived EVs treated with 5 μg/ml RNase, T-CD133+ CD133+ renal
tubular cells, F-EVs fibroblast-derived EVs. *The doses of EVs used were selected as the number of EVs produced overnight by 105 cells in serum starvation
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1 × 105 Gl-MSCs; IRI-T-CD133+ mice (n = 6) injected with
1 × 105 T-CD133+ cells. The animals were sacrificed
3 weeks after intervention.
Renal function
Blood samples for the measurement of plasma creatinine
and blood urea nitrogen (BUN) were collected at 2 days
after IRI from the different AKI groups and at 3 weeks
from the long-term four groups of mice. Creatinine con-
centrations were determined using a colorimetric micro-
plate assay based on the Jaffe reaction (Quantichrome
Creatinine Assay, BioAssay Systems, Hayward, CA,
USA). Creatinine levels that exceeded 0.3 mg/dl were
considered abnormal (normal range in our laboratory: 0.1
to 0.3 mg/dl). BUN was measured by direct quantification
of serum urea with a colorimetric assay kit according to
the manufacturer’s protocol (Arbor Assays, Ann Arbor,
MI, USA).
Morphological studies
For renal histology, 5-μm-thick paraffin-embedded kid-
ney sections were routinely stained with hematoxylin
and eosin (Merck, Darmstadt, Germany). To evaluate
the score of the AKI, luminal hyaline casts and the cell
lose (denudation of tubular basement membrane) were
assessed in non-overlapping fields (up to 28 for each
section) using a x40 objective (high power field, HPF).
The number of casts and tubular profiles showing
necrosis were recorded in a single-blind fashion [49].
Immunohistochemistry to detect the proliferation of
tubular cells was performed by BrdU incorporation as
previously described [38]. Kidney sections were sub-
jected to antigen retrieval and stained with anti-
proliferating cell nuclear antigen (PCNA) (1:400, mono-
clonal anti-PCNA antibody; Santa Cruz Biotechnology,
Dallas, TX, USA) or with anti-BrdU (1:200, Dako North
America Inc., Carpinteria, CA, USA). Immunoperoxi-
dase staining was performed using 1:300 dilution of
anti-mouse horseradish peroxidase (HRP, Pierce, Rock-
ford, IL, USA). Scoring for BrdU- and PCNA-positive
cells was carried out by counting the number of positive
nuclei per HPF (×40) in ten randomly chosen sections of
the kidney cortex.
Confocal microscopy analysis (Zeiss LSM 5 Pascal;
Carl Zeiss International, Oberkochen, Germany) was
performed on frozen sections to assess the localization
of PKH26-labelled EVs in different organs as described
previously [38]. Nuclei were stained with Hoechst 33258
dye (Sigma-Aldrich).
Statistical analysis
Statistical analysis was performed by using the t tests,
analysis of variance (ANOVA) with Newmann–Keuls’ or
ANOVA with Dunnett’s multiple comparison tests as ap-
propriate. A p value of <0.05 was considered significant.
Results
Gl-MSCs cells are more effective in promoting the
recovery of AKI compared to T-CD133+ cells
Forty-eight hours after the induction of IRI, serum creatin-
ine and BUN markedly increased in IRI mice compared to
healthy and sham-operated mice (Fig. 1). Furthermore,
Fig. 1 Effect of different renal stem/progenitor cells and their derived EVs in IRI mice: functional evaluation. a Serum creatinine and b BUN values
at day 2 after IRI, in mice injected with vehicle alone (IRI-CTL), 1 × 105 Gl-MSCs (IRI-Gl-MSC), 400 × 106 EVs produced by Gl-MSCs (IRI-Gl-MSC-EV), 400 × 106
EVs produced by Gl-MSCs and obtained by floating process (IRI-Gl-MSC-EV-float), 400 × 106 EVs produced by Gl-MSCs and treated with RNase (IRI-RNase-Gl-
MSC-EV), 1 × 105 T-CD133+ cells (IRI-T-CD133+), 480 × 106 EVs produced by T-CD133+ cells (IRI-T-CD133+-EV), 230 × 106 EVs derived from fibroblasts (IRI-F-EV),
in healthy (normal) and in sham-operated SCID mice. Data are expressed as mean ± SD, ANOVA with Dunnett’s multiple comparison test were
performed (*p< 0.05)
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histological analysis of the kidney revealed severe tubular
damage characterized by tubular necrosis and presence of
proteinaceous casts inside the lumen of tubules in IRI mice
(Fig. 2). However, injecting mice with Gl-MSCs significantly
reduced both functional and histological alterations ob-
served in IRI mice, evaluated 48 hours after surgery (Figs. 1
and 2). Although treating IRI mice with T-CD133+ cells
was associated with a significant improvement in renal
function and morphology compared to control animals, the
treatment was not as efficient in ameliorating the recovery
after IRI as the treatment with Gl-MSCs cells. In addition,
48 hours after IRI induction, PCNA staining showed a sig-
nificant increase in tubular cell proliferation in mice treated
with Gl-MSCs compared to both control mice and mice
treated with T-CD133+ cells (Fig. 3). No significant differ-
ences, however, were observed in the rate of apoptosis
between animals treated with Gl-MSCs or T-CD133+ cells
(data not shown).
In order to evaluate the long-term effects of Gl-MSCs
and T-CD133+ cells, mice were sacrificed 3 weeks after
intervention. Analysis of the results revealed no significant
differences in the functional and histological markers of
tubular damage between the control group and the ani-
mals treated with cells (data not shown). In addition, no
signs of neoplastic lesions or mal-differentiation of the
engrafted cells were detected in the renal parenchyma
(data not shown).
Characterization of EVs derived from Gl-MSCs and T-CD133
+ cells
Cytofluorimetric analyses of Gl-MSC-EVs showed the
presence of several antigens expressed by Gl-MSCs
(CD146, CD29 and CD24), as well as the exosomal
marker CD107 (Fig. 4a). FACS analyses of T-CD133
+-EVs revealed the expression of typical CD133+ cells
markers including CD24 and CD133. In addition, T-
Fig. 2 Effect of different renal stem/progenitor cells and their derived EVs in IRI mice: renal morphology. a The number of hyaline casts and
b tubular necrosis (TN) observed under high power field (HPF: ×40) is expressed as mean ± SD. An ANOVA with Dunnett’s multiple comparison
test was performed, (*p < 0.05). c Representative micrographs of renal histology of: IRI mice injected with different treatments and sham-operated
SCID mice. Original magnification: ×20. In the representative image related to IRI-CTL intratubular hyaline cast (black arrow) and a tubule with
signs of necrosis (epithelial cell denudation and presence of intratubular cell debris) (white arrow) can be observed. IRI-CTL mice injected with vehicle alone,
IRI-Gl-MSC mice injected with GI-MSC, IRI-Gl-MSC-EV EVs produced by Gl-MSCs, IRI-Gl-MSC-EV-float EVs produced by Gl-MSCs and obtained by floating
process, IRI-RNase-Gl-MSC-EV EVs produced by Gl-MSCs and treated with RNase, IRI-T-CD133+ T-CD133+ cells, IRI-T-CD133+-EV EVs produced by T-CD133+,
IRI-F-EV EVs derived from fibroblasts
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CD133+-EVs were also positive for SSEA4, CD29 and
CD146 (Fig. 4b). Nanosight analysis confirmed the aver-
age size of EVs derived from Gl-MSCs to be 170 nm
with a mode of 131 nm and a standard deviation of
62 nm (Fig. 4c). Furthermore, EVs from T-CD133+ had
an average size of 167 nm, a mode of 129 nm and a
standard deviation of 63 nm (Fig. 4d).
EVs derived from Gl-MSCs protect against IRI-induced AKI
To evaluate whether EVs derived from Gl-MSCs and
T-CD133+ cells were protective against AKI induced
by IRI, EVs were injected in mice through the tail
vein immediately after surgery. Blood chemistry
analysis showed that the serum creatinine and BUN
levels were significantly reduced in IRI animals
treated with Gl-MSC-EVs compared to ones treated
with T-CD133+-EVs or with the vehicle alone (Fig. 1).
No significant differences were observed between
treatment with Gl-MSC-EVs and Gl-MSCs (Figs. 1
and 2). The treatment of IRI mice with EVs derived
from human fibroblasts had no protective effect what-
soever on AKI suggesting the specific therapeutic role
of EVs derived from Gl-MSCs (Figs. 1 and 2). Futher-
more, on comparing IRI mice treated with Gl-MSC-
EVs to IRI mice treated with vehicle alone showed
that there was a marked increase in tubular prolifera-
tion in the former compared to the latter as quanti-
fied by PCNA (Fig. 3) and BrdU staining (Additional
file 1: Figure S1).
Moreover, we observed an improvement in renal func-
tion, morphology and tubular proliferation using Gl-
MSC-EVs obtained by floating to exclude contamination
of non-vesicular RNA and proteins comparable to that
obtained with Gl-MSC-EVs (Figs. 1, 2 and 3 and
Fig. 3 Renal cell proliferation in IRI-mice treated with different stem/progenitor cells and their derived EVs. a Quantification of PCNA-positive
cells/high power field (HPF: ×40) was performed in renal sections of IRI mice injected with vehicle alone (IRI-CTL), 1 × 105 Gl-MSCs (IRI-Gl-MSC),
400 × 106 EVs from Gl-MSCs (IRI-Gl-MSC-EV), 400 × 106 EVs from Gl-MSCs purified by floating process (IRI-Gl-MSC-EV-float), 400 × 106 EVs from Gl-MSCs and
treated with RNase (IRI-RNase-Gl-MSC-EV), 1 × 105 T-CD133+ cells (IRI-T-CD133+), 480 × 106 EVs produced by T-CD133+ cells (IRI-T-CD133+-EV),
230 × 106 EVs derived from fibroblasts (IRI-F-EV), and in sham-operated SCID mice. ANOVA with Dunnett’s multiple comparison test was
performed, (*p < 0.05). b Representative micrographs of PCNA staining preformed on section of kidneys of IRI-AKI mice injected with different
treatments. Original magnification: ×40
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Additional file 1: Figure S1). Whereas RNA in floating
EVs was not reduced by physiological doses of RNase
(see “Methods”), 5 μg/ml RNase was found to degrade
vesicle-associated RNA as seen by bioanalyzer profiling
(Fig. 5). Furthermore, RNase-treated EVs were ineffective
in improving both kidney function and histological IRI
recovery (Figs. 1, 2 and 3). Altogether, these results sug-
gest that vesicular RNA was responsible for the benefi-
cial effect of EVs in IRI mice.
Bio-distribution of EVs in IRI-AKI mice
Subsequently, the bio-distribution of EVs was checked
by confocal microscopy at different time points (1, 6
and 24 hours) after injecting PKH26-labelled EVs in
IRI mice. Interestingly, the labelled Gl-MSC-EVs
could be detected in the kidneys of IRI mice as early
as 1 hour after injection and subsequently 6 hours
later especially in the tubules (Fig. 6b, c). However,
24 hours after administration only few EVs could be
observed in the tubules of IRI mice (Fig. 6d). No
significant accumulation of EVs was detected in the
kidney of sham-operated mice (Fig. 6a). The bio-
distribution observed in mice treated with Gl-MSC-
EVs was also seen in mice treated with T-CD133
+-EVs with a maximum detection of EVs in the tu-
bules 1 hour after injection; however, this decreased
at 6 hours and 24 hours subsequently (Fig. 6e-g). Al-
though a slight amount of fibroblast-EVs were detected
in the tubules 1 hour after injection, they failed to accu-
mulate compared to the Gl-MSC-EVs and T-CD133+-EVs
(Fig. 6 h-l). A significant buildup of Gl-MSC-EVs, T-
CD133+-EVs and fibroblast-EVs was observed in the liver
Fig. 4 Characterization of EV surface markers and size. Representative FACS analyses of the expression of specific mesenchymal stromal cell and renal
progenitor cell markers by Gl-MSC-EVs (a) and T-CD133+-EVs (b). White-filled histograms indicate the isotypic controls. c-d NTA analysis of Gl-MSC-EVs
(c) and of T-CD133+-EVs (d). Four different preparations were tested with similar results
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of IRI mice both at 1 and 6 hours, respectively (Fig. 7b-c,
e-f, h-i) and the same in sham-operated mice as well
(Fig. 7a). No EVs were detected in the liver after 24 hours
post administration (Fig. 6d, g, l).
MicroRNA profiling in Gl-MSC-EVs and comparative
pathway analyses
By performing a TaqMan™ array miRNA analysis we iden-
tified 62 miRNAs (Table 3) that were specifically
expressed in Gl-MSC-EVs (Ct <35) and not in fibroblast-
EVs (Ct >35). A target prediction analysis was performed
using the Funrich tool software which identified 7318
gene targets by the selected miRNAs. The biological pro-
cesses over-represented by the predicted targeted genes of
miRNAs from Gl-MSC-EVs were related to nucleic acid
metabolism, transport, cell communication, regulation of
cell growth and gene expression (p <0.05) (Fig. 8).
Discussion
In this study, we found that Gl-MSCs injected intraven-
ously soon after kidney revascularization contributed to-
wards reducing ischemic damage in an experimental
Fig. 5 Characterization of EV RNA content. Representative bioanalyzer profiles, showing the size distribution of total RNA extracted from Gl-MSCs
and Gl-MSC-EVs. The first peak (left side of each panel) represents an internal standard. The two peaks of ribosomal RNA 18S and 28S are detect-
able in cells (a) and barely detectable in the corresponding EVs (b). EVs exhibited a relevant peak of small RNAs. After treatment with RNase A (c),
RNAs inside EVs were degraded
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model of IRI-induced AKI. This effect was mimicked by
EVs released from Gl-MSCs suggesting their involve-
ment in a paracrine fashion towards the beneficial effects
on renal ischemic damage induced by IRI. In contrast,
both CD133+ renal progenitor cells isolated from the tu-
bules and their subsequent EVs did not exhibit the same
protective potential on IRI-induced AKI.
The presence of MSCs in the glomeruli has been shown
in both rodents and humans [43, 44]. Gl-MSCs isolated
from adult human-decapsulated glomeruli were positive for
both mesenchymal stem cell markers (CD146, CD105,
CD44, CD73, CD29) and renal stem cell markers such as:
CD24 and PAX-2. Gl-MSCs were shown to be multipotent
cells with the ability to differentiate into several mesenchy-
mal cell types such as adipocytes, osteocytes, chondrocytes,
as well as specific renal cells such as podocytes and mesan-
gial cells [44]. Moreover, Gl-MSCs derived from cross-sex
transplantation demonstrated the presence of genetic
phenotype of the donor kidney, suggesting that the
MSCs derived were from the resident population in the
kidney rather than from the bone marrow of the recipient
patient [44]. Consequently, MSCs isolated from renal
murine tissues also express a specific pattern of renal
genes not observed in MSCs of marrow origin, therefore
possibly suggesting renal MSCs to have a memory of
tissue origin [50].
Several studies have demonstrated the beneficial effects
of renal resident and exogenous stem/progenitor cells in
repairing kidney damage after toxic or ischemic AKI
[9–12, 17, 23], however, no studies have been re-
ported on the effects of renal resident MSCs. Interest-
ingly, the process by which both exogenous and renal
resident stem/progenitor cells exert their therapeutic
effects have been attributed to paracrine mechanisms
[24, 26, 30, 38, 42]. Numerous reports have indicated
that there was a minimal incorporation of exogenous
Fig. 6 Distribution of EVs in the kidney after in vivo injection. Representative micrographs of kidney frozen tissue sections of mice injected with
PKH26-labelled EVs (red) and stained with laminin antibody (green). Nuclei were stained in blue with Hoechst. a Distribution of Gl-MSC-EVs, T-CD133+-EVs
and fibroblast-EVs in sham-operated mice. The distribution of Gl-MSC-EVs in tubules of IRI mice at 1 (b), 6 (c) and 24 (d) hours after administration. The
distribution of T-CD133+-EVs in tubules of IRI mice at 1 (e), 6 (f) and 24 (g) hours after administration. The distribution of fibroblast-EVs in tubules of IRI mice
at 1 (h), 6 (i) and 24 (l) hours after administration. Original magnification: ×40, except (a) × 63
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bone marrow-derived MSCs in regenerating tubules
after administration in AKI animal models [25]. More-
over, treatment with conditioned medium from MSCs
was as effective as the cells. Several growth factors
(VEGF [30] and IGF-1 [51]), cytokines and chemokines
released by MSCs in the conditioned medium have
been suggested to contribute towards this renoprotec-
tive effect [24, 29]. EVs were also found to mediate the
biological effects of MSCs in several experimental
models [52–57], mainly by entering the target cells
through specific receptors or by membrane fusion and
transferring their biologically active contents such as
proteins, mRNA and miRNA. This leads to the modifi-
cation of the phenotype of recipient cells by either in-
ducing activation of molecular pathways or epigenetic
reprogramming [33, 36, 41, 46, 58, 59]. Recently, sev-
eral authors including our group have demonstrated
the protective role of EVs derived from different
sources of MSCs not only in AKI [38, 39, 60] but also
in preventing the progression of AKI to CKD [61].
In the present model of IRI-induced AKI we report
that T-CD133+ cells and T-CD133+-EVs were signifi-
cantly less effective than Gl-MSCs and their subse-
quently derived EVs (GL-MSCs-EVs). Moreover, the
specificity of Gl-MSCs-EVs was supported by the fact
that EVs derived from fibroblasts were totally ineffective
in the same setting. We also demonstrate that a single
administration of Gl-MSCs during the reperfusion phase
after renal ischemia significantly reduces kidney damage,
stimulates renal tubular cell proliferation and leads to an
improvement in overall kidney function. In addition, a
similar beneficial effect was also observed when injecting
a single dose of Gl-MSCs-EVs. However, on inactivating
the RNA in the EVs reduced their protective effect
Fig. 7 The distribution of EVs in the liver after in vivo injection. Representative micrographs of liver frozen tissue sections of mice injected with PKH26-
labelled EVs (red) and stained with laminin antibody (green). Nuclei were stained in blue with Hoechst. a The distribution of Gl-MSC-EVs, T-CD133+-EVs
and fibroblast-EVs in sham-operated mice. The distribution of Gl-MSC-EVs in the liver of IRI mice at 1 (b), 6 (c) and 24 (d) hours after administration. The
distribution of T-CD133+-EVs in the liver of IRI mice at 1 (e), 6 (f) and 24 (g) hours after administration. The distribution of fibroblast-EVs in the liver of
IRI mice at 1 (h), 6 (i) and 24 (l) hours after administration. Original magnification: ×40
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suggesting that the biological activity observed was
partly associated with the RNA content carried by EVs.
To further investigate the relevance of specific RNA
shuttled by Gl-MSC-EVs, we characterized the miRNA
content of Gl-MSC-EVs comparing it with fibroblast EVs
that were ineffective in this AKI model. What we found
was that miRNAs specifically expressed and enriched in
Gl-MSC-EVs have predicted target genes involved in
various biological processes such as nucleic acid metab-
olism, transport, cell communication, regulation of cell
growth and gene expression, which could potentially
influence the pro-regenerative process triggered by Gl-
MSC-EVs. Although the miRNA content of EVs from
different stem cell populations play an important role in
renal regeneration [62], we cannot exclude the possibility
of other molecules shuttled by EVs (e.g. growth factors,
cytokines and chemokines) or released by cells that
may also be important contributors towards the pro-
regenerative effects of Gl-MSC in IRI.
Cell therapy with stem progenitor cells including
exogenous MSCs has been proven to be effective in
kidney repair after toxic and ischemic induced-AKI,
however, this mode of therapy has also been associ-
ated with severe side effects such as long-term mal-
Table 3 miRNAs specifically expressed by Gl-MSC EVs and not
by fibroblast EVs
miRNA name RQ
hsa-miR-299-5p 744029,35
hsa-miR-23a-3p 26432,04
hsa-miR-302b-3p 25250,07
hsa-miR-485-5p 23058,32
hsa-let-7f-5p 15771,15
hsa-miR-299-3p 11417,82
hsa-miR-654-5p 9548,11
hsa-miR-296-3p 8522,14
hsa-miR-302a-3p 5776,58
hsa-miR-139-3p 4959,57
hsa-miR-200b-3p 3600,55
hsa-miR-326 3468,27
hsa-miR-887-3p 3189,25
hsa-miR-505-3p 3017,21
hsa-miR-429 2670,70
hsa-miR-148b-3p 2176,81
hsa-miR-122-5p 2140,90
hsa-miR-449b-5p 2069,40
hsa-miR-15a-5p 1258,95
hsa-miR-215-5p 1257,20
hsa-miR-135b-5p 1162,49
hsa-miR-487a-3p 1069,71
hsa-miR-338-3p 1066,75
hsa-miR-409-5p 1033,27
hsa-miR-367-3p, 987,06
hsa-miR-23b-3p 870,08
hsa-miR-490-3p 674,18
hsa-miR-551b-3p 634,73
hsa-miR-654-3p 593,05
hsa-miR-147a 573,64
hsa-miR-548d-5p 480,04
hsa-miR-422a 467,23
hsa-miR-597-5p 410,72
hsa-miR-329-3p 397,00
hsa-miR-330-5p 353,61
hsa-miR-629-5p 313,00
hsa-miR-589-5p 247,28
hsa-miR-98-5p 211,86
hsa-miR-375 209,38
hsa-miR-545-3p 180,77
hsa-miR-146b-3p 159,56
hsa-miR-542-3p 139,68
hsa-miR-523-3p 133,81
Table 3 miRNAs specifically expressed by Gl-MSC EVs and not
by fibroblast EVs (Continued)
hsa-miR-518e-3p 132,42
hsa-miR-501-3p 130,96
hsa-miR-576-5p 129,34
hsa-miR-141-3p 127,38
hsa-miR-32-5p 126,59
hsa-miR-182-5p 115,60
hsa-miR-492 102,89
hsa-miR-511-5p 102,61
hsa-miR-627-5p 98,91
hsa-miR-450b-5p 68,40
hsa-miR-517a-3p 49,45
hsa-miR-570-3p 44,82
hsa-miR-342-5p 39,97
hsa-miR-517c-3p 38,64
hsa-miR-522-3p 33,08
hsa-miR-330-3p 22,93
hsa-miR-576-3p 19,88
hsa-miR-449a 13,55
hsa-miR-369-5p 11,64
Cutoff setting: fibroblast EVs Ct >35; Gl-MSC EVs Ct <35
Gl-MSC glomerular mesenchymal stromal cells, EVs extracellular vesicles
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differentiation of the engrafted cells [63] and the de-
velopment of neoplastic lesions [64]. In addition,
Tögel et al. reported that administration of bone mar-
row derived-MSCs in an experimental model of toxic
AKI, could induce granulocytosis that worsens the
intra-renal damage [65]. In addition, Burger et al. also
demonstrated that injecting human umbilical cord-
derived progenitor CD133+ cells in ischemic induced-
AKI unexpectedly exacerbated the kidney damage
[66]. However, in our study we did not find any
malignant lesions or mal-differentiation of the
engrafted cells in the renal parenchyma 3 weeks after
cell administration.
Conclusions
In conclusion, in this study we demonstrate for the first
time that Gl-MSCs may contribute towards kidney repair
after ischemic AKI. The mechanism can at least in part be
ascribed to the release of EVs that are able to mimic the
effect of Gl-MSCs.
Additional file
Additional file 1: Figure S1. Renal cell proliferation in IRI-mice treated
with Gl-MSCs-derived EVs. (A) Quantification of BrdU-positive cells/high
power field (HPF) was performed in renal sections of IRI mice injected
with vehicle alone (IRI-CTL), 400 × 106 EVs produced by Gl-MSCs (IRI-Gl-
MSC-EV), 400 × 106 EVs produced by Gl-MSCs and obtained by floating
process (IRI-Gl-MSC-EV-float), 400 × 106 EVs produced by Gl-MSCs and
treated with RNase (IRI-RNase-Gl-MSC-EV), and in sham-operated SCID
mice. ANOVA with Dunnett’s multiple comparison test was performed,
(*p <0.05). (B) Representative micrographs of BrdU staining preformed on
section of kidneys 2 days after IRI and treatments injection. Original
magnification: ×40. (DOCX 135 kb)
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